{
    "clinical_study": {
        "@rank": "90841", 
        "arm_group": [
            {
                "arm_group_label": "Group A (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg"
            }, 
            {
                "arm_group_label": "Group B (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 5ug/kg"
            }, 
            {
                "arm_group_label": "Group C (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg"
            }, 
            {
                "arm_group_label": "Group D (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg"
            }, 
            {
                "arm_group_label": "Group E (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg"
            }, 
            {
                "arm_group_label": "Group F (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg"
            }, 
            {
                "arm_group_label": "Group G (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg"
            }, 
            {
                "arm_group_label": "Group H (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg"
            }, 
            {
                "arm_group_label": "Group I (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg"
            }, 
            {
                "arm_group_label": "Group J (Part A)", 
                "arm_group_type": "Experimental", 
                "description": "GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg"
            }, 
            {
                "arm_group_label": "Group K (Part B)", 
                "arm_group_type": "Experimental", 
                "description": "Among Arm groups in Part A, 4 optimal doses will be selected and used as Arm group in Part B."
            }, 
            {
                "arm_group_label": "Group L (Part B)", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous administration of NESP (Aranesp) at dose of 30 ug every week\nsubcutaneous administration of NESP (Aranesp) at dose of 30 ug every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of study is\n\n        -  Part A : To explore the optimal fixed starting dose and dosing interval of GX-E2\n\n        -  Part B : To evaluate the proof of concept (POC) of GX-E2"
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anemia", 
            "Chronic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The secondary objective of study is to evaluate:\n\n        -  change of red blood cell indices in anemic patients with chronic kidney disease\n           receiving hemodialysis/peritoneal dialysis when administering GX-E2\n           intravenously/subcutaneously\n\n        -  change of reticulocyte indices in anemic patients with chronic kidney disease receiving\n           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously\n\n        -  safety of GX-E2 when administering intravenously/subcutaneously\n\n        -  incidence of blood transfusion in anemic patients with chronic kidney disease receiving\n           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously\n\n        -  Immunogenicity in anemic patients with chronic kidney disease receiving\n           hemodialysis/peritoneal dialysis when administering GX-E2 intravenously/subcutaneously"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  \u226518 yr of age\n\n          -  Chronic Kidney diseases with hemodialysis, peritoneal dialysis\n\n          -  Adequate transferrin saturation (\u226520%), serum ferritin (\u2265100g/dl)\n\n          -  Should have received Vitamine B12 \u2265 3 months before the first dose of study agent\n\n          -  Should have received Folate  \u22653 months before the first dose of study agent\n\n          -  No erythropoietin (EPO) therapy within 2month before the planned first dose of GX-E2\n             and Hb<10g/dL or No EPO therapy within month before the planned first dose of GX-E2\n             and Hb<10g/dL\n\n        Exclusion Criteria:\n\n          -  Uncontrolled hypertension\n\n          -  Uncontrolled arrhythmia\n\n          -  History of acute or chronic bronchospastic disease (including asthma and  chronic\n             obstructive pulmonary disease)\n\n          -  History of hypersensitivity to the study drug or to similar drug\n\n          -  aspartate aminotransferase/alanine aminotransferase (ALT/AST) > 3 times Upper Normal\n             Limit of Normal (UNL)\n\n          -  Absolute neutrophil count \u2264 1,500 per microliter (uL)\n\n          -  Donation or loss of \u2265400 milliliter (mL) of blood within 8 weeks prior to first dose\n\n          -  Major surgery within 3 months\n\n          -  Grand Mal epilepsy\n\n          -  History of drug or alcohol abuse in the 6 months prior to Screening\n\n          -  Participation in any clinical investigation in the 4 week period prior to dosing\n\n          -  Refractory of erythropoiesis stimulating agent (ESA) treatment\n\n          -  Systemic hematologic diseases (e.g. Pure red cell anemia, sickle cell anemia,\n             myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044653", 
            "org_study_id": "GX-E2(EPO-hyFc)_P2"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A (Part A)", 
                    "Group B (Part A)", 
                    "Group C (Part A)", 
                    "Group D (Part A)"
                ], 
                "description": "Each Group hemodialysis patients (n=10) will be administered GX-E2 5ug/kg to 8ug/kg", 
                "intervention_name": "GX-E2", 
                "intervention_type": "Drug", 
                "other_name": "GC1113"
            }, 
            {
                "arm_group_label": [
                    "Group E (Part A)", 
                    "Group F (Part A)", 
                    "Group G (Part A)", 
                    "Group H (Part A)", 
                    "Group I (Part A)", 
                    "Group J (Part A)"
                ], 
                "description": "Each Group Peritoneal dialysis (n=10) will be administered GX-E2 3ug/kg to 8ug/kg", 
                "intervention_name": "GX-E2", 
                "intervention_type": "Drug", 
                "other_name": "GC1113"
            }, 
            {
                "arm_group_label": "Group K (Part B)", 
                "description": "Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered GX-E2 3ug/kg to 8ug/kg", 
                "intervention_name": "GX-E2", 
                "intervention_type": "Drug", 
                "other_name": "GC1113"
            }, 
            {
                "arm_group_label": "Group L (Part B)", 
                "description": "Each Group Hemodialysis (n=25) and Peritoneal dialysis (n=25) will be administered NESP 30ug", 
                "intervention_name": "NESP (Aranesp)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aranesp", 
                    "Darbepoetin alfa"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darbepoetin alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Phase 2", 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "contact": {
                "email": "yangch@catholic.ac.kr", 
                "last_name": "Yang Chul-Woo, Director", 
                "phone": "82-2-2258-6851"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul St.Mary'S Hospital"
            }, 
            "investigator": {
                "last_name": "Yang Chul-Woo, Director", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "12", 
        "official_title": "Phase II Clinical Trial to Explore the Optimal Fixed Starting Dose & Dosing Interval and to Evaluate the Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease and Receiving Hemodialysis (HD) / Peritoneal Dialysis (PD)", 
        "overall_official": {
            "affiliation": "222 Banpo-daero,Seocho-gu,Seoul 137-701 Korea", 
            "last_name": "Chul-Woo Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "average change of Hemoglobin level", 
            "safety_issue": "No", 
            "time_frame": "change from baseline in Hemoglobin level at 6 weeks (part A) & 14 weeks (part B)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change of red blood cell indices", 
                "safety_issue": "No", 
                "time_frame": "change from baseline in red blood cell indices at 6 weeks(part A) & 14 weeks (part B)"
            }, 
            {
                "measure": "change of reticulocyte indices", 
                "safety_issue": "No", 
                "time_frame": "change from baseline in reticulocyte indices at 6 weeks (part A) & 14 weeks (part B)"
            }, 
            {
                "measure": "incidence, degree, outcome of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "during 6 weeks of study period (part A) & 14 weeks of study period (part B)"
            }, 
            {
                "measure": "incidence, frequency, amount of blood transfusion", 
                "safety_issue": "No", 
                "time_frame": "during 6 weeks of study period (part A) & 14 weeks of study period (part B)"
            }, 
            {
                "measure": "immunogenicity: ratio of neutralizing antibody & binding antibody in subjects", 
                "safety_issue": "Yes", 
                "time_frame": "comparison from pre-treatment to post-treatment"
            }
        ], 
        "source": "Genexine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genexine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}